 | Up a level |
Journal Article
Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N. and Loibl, S. (2022). Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Ann. Oncol., 33 (7). S. S615 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Labidi-Galy, S. I., Schneeweiss, A., Sinn, H. P., Blohmer, J-U., Romanens, L., Zahm, D-M., Huober, J., Dohnal, D., Link, T., Hanusch, C., Jackisch, C., Fasching, P. A., Solbach, C., Rhiem, K. E., Denkert, C., Weber, K. E., Lederer, B., Untch, M., Loibl, S. and Furlanetto, J. (2021). Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto. Ann. Oncol., 32. S. S49 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Link, T., Blohmer, J-U., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Schmitt, W. D., Jackisch, C., Rhiem, K. E., Hanusch, C., Denkert, C., Sinn, B. V., Engels, K., Nekljudova, V. and Loibl, S. (2020). GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann. Oncol., 31. S. S308 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V. and Loi, S. (2022). A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa. Ann. Oncol., 33 (7). S. S627 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J. and Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann. Oncol., 32. S. S443 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Tuechler, A., Remy, R., Dick, J., Ernst, C., Bluemcke, B., Lakeman, I. M. M., van Asperen, C. J., Devilee, P., Bredart, A., Rhiem, K. E., Stoppa-Lyonnet, D., Schmutzler, R. K. and Hahnen, E. (2021). Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result. Ann. Oncol., 32. S. S1104 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041